» Articles » PMID: 23574002

Mini-review: Lactoferrin: a Bioinspired, Anti-biofilm Therapeutic

Overview
Journal Biofouling
Specialty Biology
Date 2013 Apr 12
PMID 23574002
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

Medically relevant biofilms have gained a significant level of interest, in part because of the epidemic rise in obesity and an aging population in the developed world. The associated comorbidities of chronic wounds such as pressure ulcers, venous leg ulcers, and diabetic foot wounds remain recalcitrant to the therapies available currently. Development of chronicity in the wound is due primarily to an inability to complete the wound healing process owing to the presence of a bioburden, specifically bacterial biofilms. New therapies are clearly needed which specifically target biofilms. Lactoferrin is a multifaceted molecule of the innate immune system found primarily in milk. While further investigation is warranted to elucidate mechanisms of action, in vitro analyses of lactoferrin and its derivatives have demonstrated that these complex molecules are structurally and functionally well suited to address the heterogeneity of bacterial biofilms. In addition, use of lactoferrin and its derivatives has proven promising in the clinic.

Citing Articles

Lactoferrin Affects the Viability of Bacteria in a Biofilm and the Formation of a New Biofilm Cycle of A2.

Ruiz-Mazon L, Ramirez-Rico G, de la Garza M Int J Mol Sci. 2024; 25(16).

PMID: 39201405 PMC: 11355051. DOI: 10.3390/ijms25168718.


Combinatory Use of hLF(1-11), a Synthetic Peptide Derived from Human Lactoferrin, and Fluconazole/Amphotericin B against Reveals a Synergistic/Additive Antifungal Effect.

Brouwer C, Theelen B, van der Linden Y, Sarink N, Rahman M, Alwasel S Antibiotics (Basel). 2024; 13(8).

PMID: 39200089 PMC: 11351325. DOI: 10.3390/antibiotics13080790.


Application of biofilm dispersion-based nanoparticles in cutting off reinfection.

Li X, Lin S, Wang Y, Chen Y, Zhang W, Shu G Appl Microbiol Biotechnol. 2024; 108(1):386.

PMID: 38896257 PMC: 11186951. DOI: 10.1007/s00253-024-13120-7.


Targeting Intracellular Bacteria with Dual Drug-loaded Lactoferrin Nanoparticles.

Andima M, Boese A, Paul P, Koch M, Loretz B, Lehr C ACS Infect Dis. 2024; 10(5):1696-1710.

PMID: 38577780 PMC: 11091908. DOI: 10.1021/acsinfecdis.4c00045.


The chronic wound milieu changes essential oils' antibiofilm activity-an in vitro and larval model study.

Brozyna M, Dudek B, Kozlowska W, Malec K, Paleczny J, Detyna J Sci Rep. 2024; 14(1):2218.

PMID: 38278929 PMC: 10817982. DOI: 10.1038/s41598-024-52424-6.


References
1.
Hu W, Zhao J, Wang J, Yu T, Wang J, Li N . Transgenic milk containing recombinant human lactoferrin modulates the intestinal flora in piglets. Biochem Cell Biol. 2012; 90(3):485-96. DOI: 10.1139/o2012-003. View

2.
Oseas R, Yang H, Baehner R, Boxer L . Lactoferrin: a promoter of polymorphonuclear leukocyte adhesiveness. Blood. 1981; 57(5):939-45. View

3.
He J, Furmanski P . Sequence specificity and transcriptional activation in the binding of lactoferrin to DNA. Nature. 1995; 373(6516):721-4. DOI: 10.1038/373721a0. View

4.
Mah T, Pitts B, Pellock B, Walker G, Stewart P, OToole G . A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature. 2003; 426(6964):306-10. DOI: 10.1038/nature02122. View

5.
Wild S, Roglic G, Green A, Sicree R, King H . Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004; 27(5):1047-53. DOI: 10.2337/diacare.27.5.1047. View